34 results on '"Ho, G.F."'
Search Results
2. P2.10-03 Mechanisms of Acquired Resistance to ALK Inhibitors Using Plasma Sequencing - Preliminary Data from the ATORG004 Study
3. Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial
4. 334P Patient-reported outcomes with cemiplimab versus chemotherapy in advanced non-small cell lung cancer (aNSCLC): Geographic region subgroups in EMPOWER-Lung 1
5. 362P Intracranial activity of dacomitinib in treatment naïve advanced EGFR mutated non-small cell lung cancer (NSCLC): Prespecified subgroup analysis of the ATORG-003 trial
6. 327P Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-lung 1 trial
7. LBA54 Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-Lung 1 trial
8. 652O Randomized phase III VANCE study: Gemcitabine and carboplatin (GC) followed by Epstein Barr virus-specific autologous cytotoxic T lymphocytes (EBV-CTL) versus the same chemotherapy as first-line treatment for advanced nasopharyngeal carcinoma (NPC)
9. LBA29 Aspirin after standard adjuvant therapy for colorectal cancers (ASCOLT): An international, phase III, randomised, placebo-controlled trial
10. 1337P Real-world utilization and outcomes of dacomitinib as first-line therapy in Asian patients with advanced EGFR mutation–positive NSCLC: An interim analysis of the ARIA study
11. 105P Prospective, open-label, observational study of cetuximab for metastatic colorectal carcinoma (mCRC): The OPTIM1SE study
12. PO-178: A single institutional audit of setup errors for 3DCRT rectal cancers
13. Comparison of pattern of disease progression and prevalence of acquired T790M mutation in Malaysia patients with EGFR mutant lung adenocarcinoma upon failure of first-line afatinib, gefitinib and erlotinib
14. Molecular profiling of non-small cell lung cancer (NSCLC) in Asia with targeted next-generation sequencing (NGS): Interim analysis of a co-operative group study (ATORG-001)
15. Needs of cancer patients in an Asian setting
16. Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma
17. EP1.14-17 Acquired T790M Mutation in Patients Failing Treatment with First or Second-Generation EGFR-Tyrosine Kinase Inhibitors
18. Effectiveness of Breast Care Nurse Led Video Orientation Programme on Information and Navigation for Newly Diagnosed Breast Cancer Patients at University Malaya Medical Center, Malaysia
19. LBA6 A phase II, single arm, open label, Simon two-stage study of pembrolizumab in metastatic HER2-negative breast cancer patients: Evaluation of impact of germline variants in APOBEC3B (AUROR).
20. 494P - Comparison of pattern of disease progression and prevalence of acquired T790M mutation in Malaysia patients with EGFR mutant lung adenocarcinoma upon failure of first-line afatinib, gefitinib and erlotinib
21. 487P - Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma
22. 422O - Needs of cancer patients in an Asian setting
23. 373P - Molecular profiling of non-small cell lung cancer (NSCLC) in Asia with targeted next-generation sequencing (NGS): Interim analysis of a co-operative group study (ATORG-001)
24. Comparison of planned and measured rectal dose in-vivo during high dose rate Cobalt-60 brachytherapy of cervical cancer
25. In vivo skin dose measurement using MOSkin detectors in tangential breast radiotherapy
26. 1889 Prospective, non-randomised, open-label study of UDPgluconoryltransferase (UGT) 2B17 genotype as a predictive marker of exemestane pharmacokinetics (PK) in post-menopausal hormone receptor (HR)-positive Asian metastatic breast cancer (MBC) patients progressing after prior endocrine therapy
27. 1833 Prognostic factors in patients with breast cancer and brain metastases: Implications for a resource limited country
28. P0170 Trastuzumab for HER2-positive breast cancer: Experience from a middle-income Asian country
29. Prevalence and characteristics associated with default of treatment and follow-up in patients with cancer
30. Survival and Quality of Life Data from the Act One Randomised, Double-Blind, Placebo-Controlled, Phase Ii Study of Espindolol for the Treatment and Prevention of Cachexia in Patients with Stage III / Iv Non-Small Cell Lung Cancer or Colorectal Cancer
31. OP0007 What if all cancer patients in Malaysia had access to the best available care: How many deaths are avoidable?
32. OP0005 Performance of predict tool in predicting breast cancer survival in an Asian setting
33. P0140 Second line aflibercept/folfiri chemotherapy in metastatic colorectal cancer in a single institution in a south east asian country: A case series
34. 487P - Survival and Quality of Life Data from the Act One Randomised, Double-Blind, Placebo-Controlled, Phase Ii Study of Espindolol for the Treatment and Prevention of Cachexia in Patients with Stage III / Iv Non-Small Cell Lung Cancer or Colorectal Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.